Patents by Inventor Steven E. Cwirla

Steven E. Cwirla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF IL-7R-ALPHA-GAMMA AGONIST PEPTIDES IN CELL MANUFACTURING
    Publication number: 20240100159
    Abstract: The use of IL-7R??c agonist peptides in cell manufacturing is disclosed. The IL-7R??c agonist peptides can facilitate the selective growth of immune cell populations. Culture media comprising the IL-7R??c agonist peptides, methods of expanding a target immune cell population, and methods of manufacturing a target immune cell population are disclosed. The enriched immune cell populations can be used in immunotherapy.
    Type: Application
    Filed: September 6, 2023
    Publication date: March 28, 2024
    Inventors: WILLIAM J. DOWER, MICHAEL C. NEEDELS, RONALD W. BARRETT, ALICE V. BAKKER, STEVEN E. CWIRLA, SUNIL BAJAD, INKYUNG PARK
  • USE OF IL-2R-BETA-GAMMA AGONIST PEPTIDES IN CELL MANUFACTURING
    Publication number: 20240101959
    Abstract: The use of IL-2R??c agonist peptides in cell manufacturing is disclosed. The IL-2R??c agonist peptides can facilitate the selective growth of immune cell populations. Culture media comprising the IL-2R??c agonist peptides, methods of expanding a target immune cell population, and methods of manufacturing a target immune cell population are disclosed. The enriched immune cell populations can be used in immunotherapy.
    Type: Application
    Filed: September 6, 2023
    Publication date: March 28, 2024
    Inventors: WILLIAM J. DOWER, MICHAEL C. NEEDELS, RONALD W. BARRETT, ALICE V. BAKKER, STEVEN E. CWIRLA, SUNIL BAJAD, INKYUNG PARK
  • IL-7R-ALPHA-GAMMA BINDING COMPOUNDS
    Publication number: 20230357358
    Abstract: IL-7R??c binding compounds and pharmaceutical compositions comprising the IL-7R??c binding compounds are disclosed. IL-7R??c bonding compounds can act as IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.
    Type: Application
    Filed: July 11, 2023
    Publication date: November 9, 2023
    Inventors: WILLIAM J. DOWER, MICHAEL C. NEEDELS, RONALD W. BARRETT, ALICE V. BAKKER, STEVEN E. CWIRLA
  • IL-2R-BETA-GAMMA BINDING COMPOUNDS
    Publication number: 20230331801
    Abstract: IL-2R??c binding compounds, and pharmaceutical compositions comprising the IL-2R??c binding compounds are disclosed. IL-2R??c binding compounds can act as IL-2R agonists and are useful in treating cancer, autoimmune diseases and inflammatory diseases.
    Type: Application
    Filed: May 22, 2023
    Publication date: October 19, 2023
    Applicant: MEDIKINE, INC.
    Inventors: WILLIAM J. DOWER, MICHAEL C. NEEDELS, RONALD W. BARRETT, ALICE V. BAKKER, STEVEN E. CWIRLA
  • IL-7RALPHA-GAMMA LIGAND IMMUNOGLOBULIN FUSION PROTEINS
    Publication number: 20230322880
    Abstract: IL-7R??c ligands and IL-7R??c IgG-Fc fusion proteins are disclosed. The IL-7R??c ligands and IL-7R??c IgG-Fc fusion proteins are IL-7R agonists.
    Type: Application
    Filed: December 5, 2022
    Publication date: October 12, 2023
    Inventors: WILLIAM J. DOWER, RONALD W. BARRETT, MICHAEL C. NEEDELS, STEVEN E. CWIRLA, ALICE V. BAKKER, INKYUNG PARK
  • IL-7R??c binding compounds
    Patent number: 11746139
    Abstract: IL-7R??c binding compounds and pharmaceutical compositions comprising the IL-7R??c binding compounds are disclosed. IL-7R??c bonding compounds can act as IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: September 5, 2023
    Assignee: MEDIKINE, INC.
    Inventors: William J. Dower, Michael C. Needels, Ronald W. Barrett, Alice V. Bakker, Steven E. Cwirla
  • MODIFIED ANTIBODIES
    Publication number: 20230270854
    Abstract: Provided herein are modified antibodies, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same. The modified antibodies described herein are modified with a peptide. The peptide binds at or near the antigen binding site of the antibody at physiological pH, thus reducing binding affinity of the antibody for a target antigen. At acidic pH, the binding interaction of the peptide at or near the antigen binding site is disrupted, thus enabling binding with a target antigen.
    Type: Application
    Filed: December 8, 2022
    Publication date: August 31, 2023
    Inventors: David Campbell, Ramesh Bhatt, William J. Dower, Steven E. Cwirla, Blake M. Williams
  • IL-2R-?? binding compounds
    Patent number: 11718654
    Abstract: IL-2R??c binding compounds, and pharmaceutical compositions comprising the IL-2R??c binding compounds are disclosed. IL-2R??c binding compounds can act as IL-2R agonists and are useful in treating cancer, autoimmune diseases and inflammatory diseases.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: August 8, 2023
    Assignee: MEDIKINE, INC.
    Inventors: William J. Dower, Michael C. Needels, Ronald W. Barrett, Alice V. Bakker, Steven E. Cwirla
  • IL-2alpha receptor subunit binding compounds
    Patent number: 11692009
    Abstract: Peptidyl IL-2R? ligands and compounds comprising the IL-2R? ligands are disclosed. The IL-2R? ligands and compounds such as synthetic monomers, homodimers, or heteromers and recombinant fusion proteins comprising the IL-2R? ligands can be used as targeting or imaging agents, as diagnostics or to treat cancers and autoimmune diseases.
    Type: Grant
    Filed: January 5, 2022
    Date of Patent: July 4, 2023
    Assignee: MEDIKINE, INC.
    Inventors: William J. Dower, Michael C. Needels, Ronald W. Barrett, Alice V. Bakker, Steven E. Cwirla
  • IL-2RGAMMA BINDING COMPOUNDS
    Publication number: 20230192767
    Abstract: IL-2R? ligands and IL-2R?c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R? ligands and/or the IL-2R?c ligands can be IL-2 receptor agonists.
    Type: Application
    Filed: December 5, 2022
    Publication date: June 22, 2023
    Inventors: WILLIAM J. DOWER, MICHAEL C. NEEDELS, RONALD W. BARRETT, ALICE V. BAKKER, STEVEN E. CWIRLA
  • IL-2Rgamma binding compounds
    Patent number: 11548914
    Abstract: IL-2R? ligands and IL-2R?c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R? ligands and/or the IL-2R?c ligands can be IL-2 receptor agonists.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: January 10, 2023
    Assignee: MEDIKINE, INC.
    Inventors: William J. Dower, Michael C. Needels, Ronald W. Barrett, Alice V. Bakker, Steven E. Cwirla
  • IL-2RBETA BINDING COMPOUNDS
    Publication number: 20220275026
    Abstract: IL-2R? ligands and IL-2R?c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R? ligands and/or the IL-2R?c ligands can be IL-2 receptor agonists.
    Type: Application
    Filed: May 10, 2022
    Publication date: September 1, 2022
    Inventors: WILLIAM J. DOWER, MICHAEL C. NEEDELS, RONALD W. BARRETT, ALICE V. BAKKER, STEVEN E. CWIRLA
  • IL-2RBETA binding compounds
    Patent number: 11358986
    Abstract: IL-2R? ligands and IL-2R?c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R? ligands and/or the IL-2R?c ligands can be IL-2 receptor agonists.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: June 14, 2022
    Assignee: MEDIKINE, INC.
    Inventors: William J. Dower, Michael C. Needels, Ronald W. Barrett, Alice V. Bakker, Steven E. Cwirla
  • IL-2R-BETA-GAMMA BINDING COMPOUNDS AND USES THEREOF
    Publication number: 20220119492
    Abstract: IL-2R??c binding compounds, and pharmaceutical compositions comprising the IL-2R??c binding compounds are disclosed. IL-2R??c binding compounds can act as IL-2R agonists and are useful in treating cancer, an autoimmune disease, and an inflammatory disease.
    Type: Application
    Filed: November 4, 2021
    Publication date: April 21, 2022
    Inventors: WILLIAM J. DOWER, MICHAEL C. NEEDELS, RONALD W. BARRETT, ALICE V. BAKKER, STEVEN E. CWIRLA
  • DUAL IL-2R AND IL-7R BINDING COMPOUNDS
    Publication number: 20220119465
    Abstract: Dual receptor binding compounds comprising IL-2R?, IL-7R?, and R?c ligands, and pharmaceutical compositions comprising the dual receptor binding compounds are disclosed. The dual receptor binding compounds can act as IL-2R and IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.
    Type: Application
    Filed: January 4, 2022
    Publication date: April 21, 2022
    Inventors: WILLIAM J. DOWER, MICHAEL C. NEEDELS, RONALD W. BARRETT, ALICE V. BAKKER, STEVEN E. CWIRLA
  • IL-7R-ALPHA BINDING COMPOUNDS
    Publication number: 20220119493
    Abstract: IL-7R? ligands and compounds comprising IL-7R? ligands are disclosed. The IL-7R? binding compounds include fusion proteins comprising the IL-7R? ligands and can act as IL-7R agonists.
    Type: Application
    Filed: January 5, 2022
    Publication date: April 21, 2022
    Inventors: WILLIAM J. DOWER, MICHAEL C. NEEDELS, RONALD W. BARRETT, ALICE V. BAKKER, STEVEN E. CWIRLA
  • IL-2ALPHA RECEPTOR SUBUNIT BINDING COMPOUNDS
    Publication number: 20220119453
    Abstract: Peptidyl IL-2R? ligands and compounds comprising the IL-2R? ligands are disclosed. The IL-2R? ligands and compounds such as synthetic monomers, homodimers, or heteromers and recombinant fusion proteins comprising the IL-2R? ligands can be used as targeting or imaging agents, as diagnostics or to treat cancers and autoimmune diseases.
    Type: Application
    Filed: January 5, 2022
    Publication date: April 21, 2022
    Inventors: WILLIAM J. DOWER, MICHAEL C. NEEDELS, RONALD W. BARRETT, ALICE V. BAKKER, STEVEN E. CWIRLA
  • IL-7R-? binding compounds
    Patent number: 11254729
    Abstract: IL-7R? ligands and compounds comprising IL-7R? ligands are disclosed. The IL-7R? binding compounds include fusion proteins comprising the IL-7R? ligands and can act as IL-7R agonists.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: February 22, 2022
    Assignee: MEDIKINE, INC.
    Inventors: William J. Dower, Michael C. Needels, Ronald W. Barrett, Alice V. Bakker, Steven E. Cwirla
  • Dual IL-2R and IL-7R binding compounds
    Patent number: 11248030
    Abstract: Dual receptor binding compounds comprising IL-2R?, IL-7R?, and R?c ligands, and pharmaceutical compositions comprising the dual receptor binding compounds are disclosed. The dual receptor binding compounds can act as IL-2R and IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: February 15, 2022
    Assignee: MEDIKINE, INC.
    Inventors: William J. Dower, Michael C. Needels, Ronald W. Barrett, Alice V. Bakker, Steven E. Cwirla
  • IL-2alpha receptor subunit binding compounds
    Patent number: 11248025
    Abstract: Peptidyl IL-2R? ligands and compounds comprising the IL-2R? ligands are disclosed. The IL-2R? ligands and compounds such as synthetic monomers, homodimers, or heteromers and recombinant fusion proteins comprising the IL-2R? ligands can be used as targeting or imaging agents, as diagnostics or to treat cancers and autoimmune diseases.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: February 15, 2022
    Assignee: MEDIKINE, INC.
    Inventors: William J. Dower, Michael C. Needels, Ronald W. Barrett, Alice V. Bakker, Steven E. Cwirla